Lineage Cell Therapeutics (LCTX) Other Working Capital Changes (2010 - 2026)

Lineage Cell Therapeutics' Other Working Capital Changes history runs 12 years deep, the most recent figure standing at -$3.0 million for Q2 2023.

• On a quarterly basis, Other Working Capital Changes rose 28.53% year-over-year to -$3.0 million in Q2 2023; TTM through Jun 2023 was -$9.4 million, a 4.22% decrease from a year earlier, with the FY2022 full-year figure at -$13.4 million, down 3614.21% from the prior year.
• Other Working Capital Changes eased to -$3.0 million in Q2 2023 per LCTX's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $6.5 million in Q4 2023 and bottomed at -$12.8 million in Q4 2022.
• The 5-year median for Other Working Capital Changes is -$598000.0 (2024), against an average of -$850941.2.
• Across the five-year window, Other Working Capital Changes jumped 537.93% in 2021 and slumped 5556.98% in 2022, its largest moves.
• Year by year, Other Working Capital Changes stood at -$378000.0 in 2019, then jumped by 69.31% to -$116000.0 in 2020, then plunged by 248.28% to -$404000.0 in 2021, then tumbled by 336.39% to -$1.8 million in 2022, then slumped by 67.84% to -$3.0 million in 2023.
• Per Business Quant, the three latest LCTX Other Working Capital Changes figures stand at -$3.0 million (Q2 2023), -$2.1 million (Q1 2023), and -$1.8 million (Q4 2022).